Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 14:12:625158.
doi: 10.3389/fpsyt.2021.625158. eCollection 2021.

Down and High: Reflections Regarding Depression and Cannabis

Affiliations
Review

Down and High: Reflections Regarding Depression and Cannabis

Catherine Langlois et al. Front Psychiatry. .

Abstract

In light of the recent changes in the legal status of cannabis in Canada, the understanding of the potential impact of the use of cannabis by individuals suffering from depression is increasingly considered as being important. It is fundamental that we look into the existing literature to examine the influence of cannabis on psychiatric conditions, including mood disorders. In this article, we will explore the relationship that exists between depression and cannabis. We will examine the impact of cannabis on the onset and course of depression, and its treatment. We have undertaken a wide-ranging review of the literature in order to address these questions. The evidence from longitudinal studies suggest that there is a bidirectional relationship between cannabis use and depression, such that cannabis use increases the risk for depression and vice-versa. This risk is possibly higher in heavy users having initiated their consumption in early adolescence. Clinical evidence also suggests that cannabis use is associated with a worse prognosis in individuals with major depressive disorder. The link with suicide remains controversial. Moreover, there is insufficient data to determine the impact of cannabis use on cognition in individuals with major depression disorder. Preliminary evidence suggesting that the endogenous cannabinoid system is involved in the pathophysiology of depression. This will need to be confirmed in future positron emission tomography studies. Randomized controlled trials are needed to investigate the potential efficacy of motivational interviewing and/or cognitive behavioral therapy for the treatment of cannabis use disorder in individuals with major depressive major disorder. Finally, although there is preclinical evidence suggesting that cannabidiol has antidepressant properties, randomized controlled trials will need to properly investigate this possibility in humans.

Keywords: cannabis; depression; epidemiology; impact; legalization; mechanisms of action.

PubMed Disclaimer

Conflict of interest statement

AK has consulted with Spectrum Therapeutics and Tilray in an advisory, mentorship and educational role. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Similar articles

Cited by

References

    1. Brenner P, Brandt L, Li G, DiBernardo A, Boden R, Reutfors J. Substance use disorders and risk for treatment resistant depression: a population-based, nested case-control study. Addiction. (2020) 115:768–77. 10.1111/add.14866 - DOI - PMC - PubMed
    1. Lucatch AM, Coles AS, Hill KP, George TP. Cannabis and mood disorders. Curr Addict Rep. (2018) 5:336–45. 10.1007/s40429-018-0214-y - DOI - PMC - PubMed
    1. Ferrari AJ, Charlson FJ, Norman RE, Patten SB, Freedman G, Murray CJ, et al. . Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med. (2013) 10:e1001547. 10.1371/journal.pmed.1001547 - DOI - PMC - PubMed
    1. Wycoff AM, Metrik J, Trull TJ. Affect and cannabis use in daily life: a review and recommendations for future research. Drug Alcohol Depend. (2018) 191:223–33. 10.1016/j.drugalcdep.2018.07.001 - DOI - PMC - PubMed
    1. Bloomfield MAP, Hindocha C, Green SF, Wall MB, Lees R, Petrilli K, et al. . The neuropsychopharmacology of cannabis: a review of human imaging studies. Pharmacol Ther. (2019) 195:132–61. 10.1016/j.pharmthera.2018.10.006 - DOI - PMC - PubMed

LinkOut - more resources